Möchten Sie immer auf dem neuesten Stand bleiben?

Company announcement – No. 30 / 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 29/ 2021 Interim report for Q1 2021 Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection ...

Company announcement – No. 28/ 2021Zealand Pharma launches long-term incentive program for Zealand’s Executive Management and employees for 2021Copenhagen, DK and Boston, MA,...

Company announcement – No. 27/ 2021 Zealand Pharma Hosts Conference Call on May 12 at 4 pm CET (10 am ET) to Present First Quarter Results for 2021 Copenhagen, DK and Boston, MA, U.S. May 5,...

Company announcement – No. 26/ 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 25 / 2021 Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with...

Company announcement – No. 24/ 2021 Total number of shares and voting rights in Zealand Pharma at April 30, 2021 Copenhagen, DK and Boston, MA, April 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL)...

Company announcement – No. 23 / 2021 Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors and grants for 2021 Copenhagen, DK and Boston, MA, U.S., April 29,...

Company announcement – No. 22/ 2021 Zealand Pharma's Annual General Meeting 2021 Copenhagen, April 15, 2021 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no. 20 04 50 78), held...

Company announcement – No. 21/ 2021 Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity New studies mark an important advancement of Boehringer...